Auranofin, an anti-rheumatic gold compound, modulates apoptosis by elevating the intracellular calcium concentration ([Ca2+]i) in MCF-7 breast cancer cells

Cancers

Volumn 6, Issue 4, 2014, Pages 2243-2258

  Varghese, Elizabeth ^a   Büsselberg, Dietrich ^a  

^a QATAR FOUNDATION   (Qatar)

Author keywords

Anticancer drugs; Apoptosis; Auranofin; Breast cancer; Cytotoxicity; Intracellular calcium

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; AURANOFIN; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; FLUORESCENT DYE; NIMODIPINE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM ENTRY; CALCIUM TRANSPORT; CANCER CELL DESTRUCTION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; METABOLIC PARAMETERS; MTS ASSAY; SENSITIVITY ANALYSIS;

EID: 84925456023     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6042243     Document Type: Article

References (32)

1. Frezza, M.; Hindo, S.; Chen, D.; Davenport, A.; Schmitt, S.; Tomco, D.; Dou, Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des. 2010, 16, 1813-1825.
2. Florea, A.M.; Büsselberg, D. Anti-cancer drugs interfere with intracellular calcium signaling. Neurotoxicology 2009, 30, 803-810.
3. Florea, A.M.; Büsselberg, D. Metals and breast cancer: Risk factors or healing agents? J. Toxicol. 2011, 2011, doi:10.1155/2011/159619.
4. Hanigan, M.H.; Devarajan, P. Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther. 2003, 1, 47-61.
5. Forestier, J. Rheumatoid arthritis and its treatment by gold salts. J. Lab. Clin. Med. 1935, 20, 827-840.
6. Simon, T.M.; Kunishima, D.H.; Vibert, G.J.; Lorber, A. Inhibitory effects of a new oral gold compound on HeLa cells. Cancer 1979, 44, 1965-1975.
7. Mirabelli, C.K.; Johnson, R.K.; Hill, D.T.; Faucette, L.F.; Girard, G.R.; Kuo, G.Y.; Sung, C.M.; Crooke, S.T. Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J. Med. Chem. 1986, 29, 218-223.
8. Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu, M.A.; Minghetti, G.; Fregona, D.; Fiebig, H.H.; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: A systematic study. J. Biol. Inorg. Chem. 2009, 14, 1139-1149.
9. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 2007, 42, 872-881.
10. Rigobello, M.P.; Folda, A.; Baldoin, M.C.; Scutari, G.; Bindoli, A. Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic. Res. 2005, 39, 687-695.
11. Splettstoesser, F.; Florea, A.M.; Büsselberg, D. Ip(3) receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis. Br. J. Pharmacol. 2007, 151, 1176-1186.
12. Boehning, D.; Patterson, R.L.; Sedaghat, L.; Glebova, N.O.; Kurosaki, T.; Snyder, S.H. Cytochrome C binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat. Cell Biol. 2003, 5, 1051-1061.
13. Hatano, N.; Suzuki, H.; Muraki, Y.; Muraki, K. Stimulation of human TRPA1 channels by clinical concentrations of the antirheumatic drug auranofin. Am. J. Physiol. Cell Physiol. 2013, 304, C354-C361.
14. Wong, K.; Parente, J.; Prasad, K.V.; Ng, D. Auranofin modulated cytoplasmic free calcium in neutrophils by mobilizing intracellular calcium and inhibiting protein kinase. J. Biol. Chem. 1990, 265, 21454-21461.
15. Liu, C.; Liu, Z.; Li, M.; Li, X.; Wong, Y.-S.; Ngai, S.-M.; Zheng, W.; Zhang, Y.; Chen, T. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. PLoS One 2013, doi:10.1371/journal.pone.0053945.
16. Gandin, V.; Fernandes, A.P.; Rigobello, M.P.; Dani, B.; Sorrentino, F.; Tisato, F.; Bjornstedt, M.; Bindoli, A.; Sturaro, A.; Rella, R., et al. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 2010, 79, 90-101.
17. Mokhtari, M.J.; Akbarzadeh, A.; Hashemi, M.; Javadi, G.; Mahdian, R.; Mehrabi, M.R.; Farhangi, A.; Mohammadi, H. Cisplatin induces down regulation of BCL 2 in T47D breast cancer cell line. Adv. Stud. Biol. 2012, 4, 19-25.
18. Osman, A.M.; Bayoumi, H.M.; Al-Harthi, S.E.; Damanhouri, Z.A.; Elshal, M.F. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int. 2012, doi:10.1186/1475-2867-12-47.
19. Magherini, F.; Modesti, A.; Bini, L.; Puglia, M.; Landini, I.; Nobili, S.; Mini, E.; Cinellu, M.A.; Gabbiani, C.; Messori, L. Exploring the biochemical mechanisms of cytotoxic gold compounds: A proteomic study. J. Biol. Inorg. Chem. 2010, 15, 573-582.
20. Nakaya, A.; Sagawa, M.; Muto, A.; Uchida, H.; Ikeda, Y.; Kizaki, M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. Leuk. Res. 2011, 35, 243-249.
21. Guidi, F.; Landini, I.; Puglia, M.; Magherini, F.; Gabbiani, C.; Cinellu, M.A.; Nobili, S.; Fiaschi, T.; Bini, L.; Mini, E., et al. Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. Metallomics 2012, 4, 307-314.
22. De Luca, A.; Hartinger, C.G.; Dyson, P.J.; lo Bello, M.; Casini, A. A new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofin. J. Inorg. Biochem. 2013, 119, 38-42.
23. O’Brien, M.L.; Tew, K.D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 1996, 32A, 967-978.
24. Gunes, D.A.; Florea, A.M.; Splettstoesser, F.; Büsselberg, D. Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity. Neurotoxicology 2009, 30, 194-202.
25. Wyrsch, P.; Blenn, C.; Pesch, T.; Beneke, S.; Althaus, F.R. Cytosolic Ca2+ shifts as early markers of cytotoxicity. Cell Commun. Signal. 2013, doi:10.1186/1478-811X-11-11.
26. Florea, A.M.; Büsselberg, D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3, 1351-1371.
27. Florea, A.M.; Splettstoesser, F.; Büsselberg, D. Arsenic trioxide (As2O3) induced calcium signals and cytotoxicity in two human cell lines: SY-5Y neuroblastoma and 293 embryonic kidney (HEK). Toxicol. Appl. Pharmacol. 2007, 220, 292-301.
28. Al-Taweel, N.; Varghese, E.; Büsselberg, D. Metal-based drugs, cisplatin and auranofin, disrupt [Ca2+]i homeostasis in MCF-7 breast cancer cell-line. In Proceedings of 91st Annual Meeting of The German Physiological Society, Dresden, Germany, 22-25 March 2012.
29. Al-Taweel, N.; Varghese, E.; Florea, A.M.; Büsselberg, D. Cisplatin (CDDP) triggers cell death of MCF-7 cells following disruption of intracellular calcium [Ca2+]i homeostasis. J. Toxicol. Sci. 2014, 39, 765-774.
30. Zhu, W.H.; Loh, T.T. Roles of calcium in the regulation of apoptosis in HL-60 promyelocytic leukemia cells. Life Sci. 1995, 57, 2091-2099.
31. Maruyama, T.; Kanaji, T.; Nakade, S.; Kanno, T.; Mikoshiba, K. 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of ins(1,4,5)p3-induced Ca2+ release. J. Biochem. 1997, 122, 498-505.
32. Bootman, M.D.; Collins, T.J.; Mackenzie, L.; Roderick, H.L.; Berridge, M.J.; Peppiatt, C.M. 2-aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of insp3-induced Ca2+ release. FASEB J. 2002, 16, 1145-1150.